WITHUS PHARMACEUTICALLTD Performance dei guadagni passati
Il passato criteri di controllo 4/6
WITHUS PHARMACEUTICALLTD's earnings have been declining at an average annual rate of -10.6%, while the Pharmaceuticals industry saw earnings growing at 11.7% annually. Revenues have been growing at an average rate of 11.5% per year. WITHUS PHARMACEUTICALLTD's return on equity is 8.4%, and it has net margins of 7.8%.
Informazioni chiave
-10.6%
Tasso di crescita degli utili
-77.1%
Tasso di crescita dell'EPS
| Pharmaceuticals Crescita del settore | 11.3% |
| Tasso di crescita dei ricavi | 11.5% |
| Rendimento del capitale proprio | 8.4% |
| Margine netto | 7.8% |
| Ultimo aggiornamento sui guadagni | 30 Jun 2024 |
Aggiornamenti sulle prestazioni recenti
We Think That There Are Issues Underlying WITHUS PHARMACEUTICALLTD's (KOSDAQ:330350) Earnings
May 25
We're Not Counting On WithuspharmaceuticalLtd (KOSDAQ:330350) To Sustain Its Statutory Profitability
Dec 09Recent updates
We Think That There Are Issues Underlying WITHUS PHARMACEUTICALLTD's (KOSDAQ:330350) Earnings
May 25Here's What Withuspharmaceutical Co.,Ltd.'s (KOSDAQ:330350) Shareholder Ownership Structure Looks Like
Feb 17Calculating The Intrinsic Value Of Withuspharmaceutical Co.,Ltd. (KOSDAQ:330350)
Jan 13
We're Not Counting On WithuspharmaceuticalLtd (KOSDAQ:330350) To Sustain Its Statutory Profitability
Dec 09Ripartizione dei ricavi e delle spese
Come WITHUS PHARMACEUTICALLTD guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.
Storia dei guadagni e delle entrate
| Data | Ricavi | Guadagni | Spese G+A | Spese di R&S |
|---|---|---|---|---|
| 30 Jun 24 | 98,274 | 7,652 | 49,737 | 2,084 |
| 31 Mar 24 | 90,147 | 9,194 | 42,922 | 1,517 |
| 31 Dec 23 | 80,119 | 7,959 | 37,347 | 1,868 |
| 30 Sep 23 | 68,975 | 3,264 | 34,399 | 2,067 |
| 30 Jun 23 | 65,794 | 1,606 | 32,112 | 2,410 |
| 31 Mar 23 | 63,032 | 1,057 | 30,742 | 2,615 |
| 31 Dec 22 | 64,680 | 2,479 | 29,849 | 2,357 |
| 30 Sep 22 | 64,618 | 5,424 | 27,797 | 2,108 |
| 30 Jun 22 | 62,461 | 5,282 | 27,136 | 1,852 |
| 31 Mar 22 | 61,564 | 5,089 | 26,754 | 1,586 |
| 31 Dec 21 | 57,419 | 4,264 | 26,328 | 1,420 |
| 31 Dec 20 | 53,406 | 6,652 | 22,807 | 1,807 |
| 30 Sep 20 | 52,842 | 7,075 | 22,229 | 1,983 |
| 30 Jun 20 | 52,393 | 8,039 | 21,150 | 1,512 |
| 31 Mar 20 | 53,743 | 8,742 | 21,974 | 1,149 |
| 30 Jun 19 | 51,732 | 8,661 | 20,158 | 587 |
| 30 Jun 18 | 50,945 | 8,491 | 19,302 | 0 |
| 30 Jun 17 | 49,519 | 7,332 | 19,112 | 0 |
| 30 Jun 16 | 45,878 | 7,844 | 17,542 | 0 |
| 30 Jun 15 | 41,640 | 7,147 | 12,440 | 0 |
| 30 Jun 14 | 39,192 | 6,372 | 12,588 | 0 |
Guadagni di qualità: A330350 has high quality earnings.
Margine di profitto in crescita: A330350's current net profit margins (7.8%) are higher than last year (2.4%).
Flusso di cassa libero e analisi degli utili
Analisi della crescita degli utili nel passato
Andamento degli utili: A330350's earnings have declined by 10.6% per year over the past 5 years.
Accelerare la crescita: A330350's earnings growth over the past year (376.5%) exceeds its 5-year average (-10.6% per year).
Guadagni vs Settore: A330350 earnings growth over the past year (376.5%) exceeded the Pharmaceuticals industry 21.9%.
Rendimento del capitale proprio
ROE elevato: A330350's Return on Equity (8.4%) is considered low.